Beyond Air Reaffirms FY26 Revenue Guidance at $12M-$16M

Beyond Air has reaffirmed its FY26 revenue guidance of $12-$16 million, which is below the consensus estimate of $15.95 million.

GARDEN CITY, N.Y., July 2, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company, has reaffirmed its fiscal year 2026 (FY26) revenue guidance of $12 to $16 million. This guidance is below the consensus estimate of $15.95 million, as reported by financial analysts.

The company announced its financial results for the fiscal first quarter ended June 30, 2025, revealing a significant increase in revenues. Revenue for the quarter rose 157% to $1.8 million, compared to $0.7 million in the same period last year [1]. The company attributed this growth to increased demand for its LungFit PH system and expanded international sales. Additionally, Beyond Air secured a national group purchasing agreement with Premier, Inc., which includes over 4,350 member hospitals and health systems in its network.

Beyond Air's CEO, Steve Lisi, stated, "We are driving strong market adoption of LungFit PH as we continue to break down barriers and expand our global distribution network." The company expects sustained double-digit sequential revenue growth to support its FY26 revenue guidance [1].

Financial highlights for the quarter ended June 30, 2025, include a gross profit of $0.2 million, compared to a gross loss of $0.3 million in the previous year. Research and development expenses decreased to $3.1 million from $6.0 million, primarily due to reduced costs in salaries, stock-based compensation, and clinical studies. Selling, general, and administrative expenses also decreased by $2.5 million to $4.7 million.

Despite these improvements, Beyond Air reported a net loss of $7.7 million for the quarter, reflecting a loss of $1.53 per share, basic and diluted. The company's cash burn was $4.7 million, and as of June 30, 2025, it had $6.5 million in cash, cash equivalents, and marketable securities, with total long-term debt outstanding of $11.6 million.

Beyond Air's FY26 revenue guidance is based on the company's ongoing clinical trials and regulatory approvals. The company is advancing its LungFit systems in clinical trials for severe lung infections and has partnered with The Hebrew University of Jerusalem to develop treatments for autism spectrum disorder. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO for targeting solid tumors.

Beyond Air's stock closed at $1.20 per share on July 2, 2025, down from $1.30 at the end of June 2025.

References:
[1] https://www.biospace.com/beyond-air-reports-fiscal-first-quarter-2026-financial-results-and-provides-corporate-update